Pfizer – media

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY

Monday, November 09, 2020 – 06:45am Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis Analysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005539/en/ NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE)– Pfizer Inc. (NYSE: ...
- Source: drugdu
- 1,250
- November 10, 2020
Covid-19 Pfizer
Pfizer Drug Lowers Mortality Risk by 30 Percent in a Rare Cardiac Condition

Risk of mortality in a rare cardiac condition, transthyretin amyloid cardiomyopathy, plunged by 30% on administration of Pfizer’s tafamidis in a 30-month long study on 440 patients.
- Source: Reuters
- 660
- August 29, 2018
cardiac Company Insight Pfizer
Nebraska Informs Pfizer to Prosecute Over Lethal Injection

Pfizer objected to the use of its drugs for lethal injection procedures last year by asking states to return the drugs immediately for a refund. But not all of them have halted its utilization. Hence, with an execution planned in Nebraska dated Aug. 14, a state senator is urging Pfizer to prosecute if the drug usage is not halted.
- Source: FiercePharma
- 980
- August 1, 2018
Company Insight Pfizer pharmaceutical
Phase 3 Gene Therapy Study on Hemophilia B Launched by Pfizer

Pfizer has initiated its new work on a phase 3 study of an investigational gene therapy designed to treat hemophilia B.
- Source: MedEdge
- 1,243
- July 23, 2018
Clinical Trials hemophilia Pfizer
Shortage in Drug Supplies, According to FDA

The U.S. healthcare system and the FDA have been affected by manufacturing issues at one of the largest U.S. drugmakers, Pfizer. The company’s Hospira unit is the largest producer of injectable opioid analgesics used in hospitals.
- Source: FiercePharma
- 802
- June 22, 2018
FDA Market Views Pfizer
FDA approved Pfizer biosimilar Epogen/Procrits

The FDA granted approval to Pfizer for Retacrit (epoetin alfa-epbx), which is used for the treatment of anemia, biosimilar of Amgen, a drug which generated sales closely $ 1.8 billion in the U.S market last year for Amgen and Johnson & Johnson partners. Retacrit also received the go-ahead to be used in RBC transfusions by U.S health regulators.
- Source: Ddu
- 693
- May 16, 2018
anemia New Approvals Pfizer pharma
Pfizer announces second year of UK-based startup innovation competition

Pfizer announced today that it is receiving applications for its Pfizer Healthcare Hub: London competitive grant. This is the second time that Pfizer has held the startup-focused program, which representatives from biopharmaceutical company said had a strong inaugural year in 2017.
- Source: MobiHealthNews
- 688
- April 9, 2018
Company Insights healthcare Pfizer
EMA starts review of Xtandi in non-metastatic prostate cancer

The EU medicines regulator has started its review of Astellas and Pfizer’s prostate cancer drug Xtandi in what looks likely to become a hotly contested indication - non-metastatic castration-resistant prostate cancer (nmCRPC).
- Source: pmlive
- 819
- March 23, 2018
Astellas Company Insights nmCRPC Pfizer Xtandi
Biogen buys Pfizer’s unwanted neuro med for $75M as sell-off starts

As Pfizer clears house of its unwanted neuro assets, Biogen has become a buyer for one, namely a phase 2-ready schizophrenia drug.
- Source: FierceBiotech
- 769
- March 13, 2018
Company Insight Pfizer pharmaceutical schizophrenia
Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis

Pfizer Inc. announced a positive outcome from today’s U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) meeting. The GIDAC met to discuss Pfizer’s supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib), which is currently under review by the FDA, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
- Source: finance.yahoo
- 707
- March 12, 2018
FDA Pfizer UC XELJANZ

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.